Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of net revenue recognized under our GSK Agreements

	Year Ended December 31,
(In thousands)	2014			2013			2012
Royalties from a related party	$	18,417		$	1,945		$	—
Less: amortization of capitalized fees paid to a related party		(11,066	)		(743	)		—

Royalty revenue		7,351			1,202			—
LABA collaboration(1)		—			1,815			3,629
Strategic alliance—MABA program license(2)		1,082			1,515			1,984

Total net revenue from GSK	$	8,433		$	4,532		$	5,613

(1)

Deferred revenue under this agreement was fully recognized in 2013.

(2)

We revised the estimated performance period for the MABA program based on its progress as follows: (i) in the fourth quarter of 2012, resulting in an increase to net loss of $0.1 million for the year ended December 31, 2012 and (ii) in the fourth quarter of 2013, resulting in an increase to net loss of $0.1 million for the year ended December 31, 2013. We do not expect that these revisions will have a material impact on future revenue recognized under this program